Bayer AG

Explore Bayer AG’s strategic realignment: share sale, labor cost stability, and breakthrough biologics like BAY‑001 for metastatic melanoma and BAY‑002 for diabetes, plus a crop‑protection partnership, all aimed at boosting financial health and scie…

Explore how Bayer AG’s life‑science focus shields its shares from oil‑price swings and what the upcoming earnings may reveal about resilience amid geopolitical risk.

Discover how Bayer’s new renal‑cardio drug and contrast‑media expansion is reshaping investor sentiment, boosting earnings, and positioning the company for long‑term growth.

Explore how Bayer AG’s specialty implant strategy drives 13 % core sales growth and high‑teens EBITDA, backed by custom‑fit solutions, global expansion, and disciplined cost control.

Explore Bayer AG’s market stance—steady yet flat in a volatile German market, with growth plateaued but green chemistry and digital health offering new prospects.

Provisional U.S. court approval of Bayer’s multi‑billion‑dollar Roundup settlement: financial impact, market reaction, and future risk for the agribusiness giant.

Discover Bayer AG’s early‑stage prostate‑cancer therapy showing 18% response & 9.6‑month PFS, plus a promising PSMA‑radionuclide trial, amid volatile finances and future FDA/EMA plans.

Explore how Bayer’s lawsuits over Nubeqa vs. Erleada and glyphosate reshape its pharma and crop‑science futures, affecting pricing, regulation, and stock value.

Shares of Bayer AG fall 3.8 % amid earnings cuts and regulatory delays, yet its diverse pharma, diagnostics and agro‑chemical portfolio still underpins long‑term growth and clinical gains.

Discover how Bayer’s $7.25 billion glyphosate settlement could stabilize earnings, boost investor confidence, and influence healthcare risk‑management.